



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

6923-071

APPLICATION NO.

09/070,629

APPLICANT

Palese et al.

FILING DATE

April 30, 1998

GROUP

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

50	BE	Akagi et al. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J Immunother. 1997 Jan;20(1):38-47
	BF	Durrant LG. Cancer vaccines. Anticancer Drugs. 1997 Sep;8(8):727-33. Review
	BG	Itoh et al. Development of cancer vaccine by tumor rejection antigens.Int Rev Immunol. 1997;14(2-3):153-71. Review
	BH	Kawakami et al. Human melanoma antigens recognized by T lymphocytes. Keio J Med. 1996 Jun;45(2):100-8. Review
	BI	Kawakami Y and Rosenberg SA., T-cell recognition of self peptides as tumor rejection antigens. Immunol Res. 1996;15(3):179-90. Review.
	BJ	Krainer et al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology. 1997 Nov-Dec;54(6):475-81
	BK	Maeurer et al. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res. 1996 Feb;6(1):11-24. Review.
	BL	McCabe et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res. 1995 Apr 15;55(8):1741-7
	BM	Osanto S. Vaccine Trials for the Clinician: Prospects for Tumor Antigens. Oncologist. 1997;2(5):284-299
	BN	Rosenberg et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900
	BO	Zhai et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother. 1997 Jan;20(1):15-25
	BP	Zhai et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol. 1996 Jan 15;156(2):700-10

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.